CONTENTS

October 2006


FEATURES
Is the 43rd President of the United States really science's worst-ever enemy? News editor ALISON MCCOOK consulted more than a dozen sources to find out. The answer may surprise you. Also, see how Bush's record on science stacks up with that of past presidents.
Related Articles:
Enemies of the State?
Bush's isn't the only administration to use science selectively. Here's a sampling of previous incidents.
Let's Get Political
President Bush has done his fair share of interfering in science and the scientific process. How can you fight back?
Editorial: Science and the President
Is Bush science's nemesis? Or are we being unreasonably rough on his record?
Tune in to our October 4th podcast for more on politics and science including an interview with L.A. Times reporter Joe Mathews about the real value of the stem cell initiative in California.
Science and Politics Podcast
How objective are scientists? Three-thousand responses to our online poll indicate that party affiliation strongly colors their opinions.

PER SVENNINGSSON and Nobel Prize winner PAUL GREENGARD describe how a single protein was found to link schizophrenia and depression to drugs of abuse and addiction.
More neuroscience coverage:
Meeting of the Minds
36 recommendations Europeans came up with when they gathered to talk about brain science.
Singing in the Bird Brain
The songbirds studied by Fernando Nottebohm aren't the only ones singing praises.
Patch Clamping Unhooked
How to record a single neuron in a moving animal
Ten Steps to Better Patch Clamping
An expert on the technique shares his secrets.
How It Works: Patch Clamping

Listen as senior editor Brendan Maher interviews Paul Greengard and Per Svenningson about the implications of their work on DARPP-32 and the role of p11 in Prozac's mechanism of action

Doug Bergman drove 240 miles to have his heart stabbed by a needle from the inside out. Now he hopes the stem cells that may be in that needle will change his life. Deputy editor IVAN ORANSKY traveled to Minneapolis to observe the procedure.
Related Article:
Making a Play at Regrowing Hearts
Results from the first round of controlled human stem cell trials for heart disease are in. What have we learned?
Web Extras:
Clinical Trials Database
A sortable chart showing details of several ongoing and recently terminated cardiac stem cell trials
Delivering on the Dream
Some of the cell types and delivery methods that are being investigated for the treatment of heart disease both in and out of the clinic
Podcast:
Check out our August 9 podcast to hear Kenneth Chien assess the clinical progress of adult human stem cells in cardiac care

Slideshow:
Travel to Minneapolis to watch Doug Bergman take part in the CD34 trial.
 
Our annual survey picks the 40 best academic institutions. See where yours - or the one you're considering moving to - fared. Assistant publisher MARIA W. ANDERSON highlights trends and zeroes in on what made top schools great.
ALSO THIS MONTH

SCIENCE AND THE PRESIDENT

Is Bush science's nemesis? Or are we being unreasonably rough on his record?
By Richard Gallagher

MAIL

The never-ending story of HeLa; The inequality of science; Setting the record straight on antibiotic resistance

THE AGENDA

ASHG in New Orleans; Protecting Animal Science; Talking Transmitters; Quotable Science

BITING BACK AT ANIMAL ACTIVISTS

What's on tap at this month's American Association for Laboratory Animal Science meeting
By Ted Agres

THE GOAT SEX RESEARCHER

There's nothing romantic about Larry Katz's "lab." And yet...
By Bob Grant

THE WORLD'S DENSEST BONES

How a car accident led to an important genetic discovery
By Kirsten Weir

BIOLOGY OLYMPIANS

Find out what happened when five US teenagers traveled to Argentina to compete
By Ishani Ganguli

A UK LAWN TURNS 150

What the Park Grass Experiment has to say about seed, fertilizer, and more
By Stephen Pincock

MEETING OF THE MINDS

36 recommendations Europeans came up with when they gathered to talk about brain science.
By Tinne Vandensande, Michael Rogers, and Stef Steyaert, on behalf of the Meeting of Minds Steering Committee

THE PLURAL OF ANECDOTE IS NOT AMBIEN

Aided and abetted by the press, researchers are relying more on case reports.
By Glenn McGee

BIRD FLU MADNESS

We must step up to counter the misinformation that is destroying poultry markets.
By Jack Woodall

SINGING IN THE BIRD BRAIN

The songbirds studied by Fernando Nottebohm aren't the only ones singing praises.
By Karen Hopkin

CULTURING HEPATITIS C

An unusual HCV virus strain opens the pathogen's entire life cycle to scrutiny.
By David Secko

WALKING REVOLUTION

Deciphering Kinesin's Step
By Juhi Yajnik

BEYOND GFP

Fluorescent repertoire expands with oranges, cherries
By Chandra Shekhar

PAPERS TO WATCH

Hep C Structure, Unfolded Protein Responses, and Texel Sheep Muscularity

PATCH CLAMPING UNHOOKED

How to record a single neuron in a moving animal

PREDICTING NUCLEOSOME POSITION

Research suggests a 'code' at work

SCIENTIST TO WATCH

Coleen Murphy: Immersed in the Inevitable
By Chandra Shekhar

A LAB STARTUP

You have $200,000 to spend in your new lab. What should you buy?
By Jeffrey Perkel

TEN STEPS TO BETTER PATCH CLAMPING

An expert on the technique shares his secrets.
By Areles Molleman

HOW IT WORKS: PATCH CLAMPING

By Brendan Maher

REVIVING THE DEAD

What started as a wild idea in 2000 languished, until a chance meeting in Washington created an opportunity to jumpstart a new business.
By Mark Gessler

FIVE THINGS NOT TO FORGET WHEN FORECASTING

Forecast models can become complex, but the principles for gathering and vetting data for good predictions should remain basic.
By Ken Wilan

EUROPE APPROVES FIRST TRANSGENIC DRUG

By Charles Choi

THE FOUNDER EFFECT

What happens when founders stick around companies?
By Chandra Shekhar

THE BENEFIT OF LONGER-TERM BIOTECH DEALS

By Ken Wilan

MEASURING UP

Should you be using screening tests?
By Chandra Shekhar

EQUALITY PENDING

Are women patenting as much as men?
By Charles Choi

WOUND HEALING CENTERS GET BOOST

By Charles Choi

HHMI LOOKING FOR FARM HANDS

By Juhi Yajnik

FOUNDATIONS

The First Report of Recombinant DNA
By Terry Sharrer